Houston TX 膀胱癌临床试验
31项针对 膀胱癌的研究正在 Houston及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
招募中1 期
- University of Texas MD Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
招募中1 期
- University of Texas MD Anderson Cancer Center, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中观察性研究欢迎健康志愿者
- UT MD Anderson Cancer Center, Houston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
招募中2 期
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
招募中1 期
- MD Anderson Cancer Center, Houston
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
招募中2 期
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
招募中1 期
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
招募中2 期
- The University of Texas MD Anderson Cancer Center, Houston
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
招募中3 期
- UT MD Anderson Cancer Center, Houston
- UT MD Anderson - West Houston, Houston
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
招募中1/2 期
- Texas Oncology - Gulf Coast, Houston
- Texas Oncology - Gulf Coast, Houston
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
招募中3 期
- University of Texas MD Anderson Cancer Center, Houston
Measuring Surgical Recovery After Radical Cystectomy
招募中观察性研究
- University of Texas MD Anderson Cancer Center, Houston
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
招募中3 期
- Houston Metro Urology, Houston
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
招募中1 期
- MD Anderson, Houston
- NEXT Oncology Houston, Houston
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
招募中1/2 期
- MD Anderson Cancer Center, Houston
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
招募中1 期
- MD Anderson Cancer Center, Houston
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
招募中2 期
- Houston Methodist, Houston
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
招募中2 期
- Houston Metro Urology, Houston
- Houston Methodist Hospital, Houston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
招募中1/2 期
- The University of Texas, MD Anderson Cancer Center, Houston
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
招募中1/2 期
- Houston Metro Urology, Houston
- Houston Methodist Hospital - Department of Urology, Houston
- University of Texas - MD Anderson Cancer Center, Houston
IDOV-Immune for Advanced Solid Tumors
招募中1 期
- MD Anderson Cancer Center, Houston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
招募中2 期
- University of Texas MD Anderson Cancer Center, Houston
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
招募中2 期
- The University of Texas MD Anderson Cancer Center, Houston
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
招募中1 期
- MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
招募中1 期
- Oncology Consultants, PA, Houston
- Oncology Consultants, PA., Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
招募中2 期
- Houston Methodist Neal Cancer Center, Houston
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
招募中观察性研究
- Md Anderson Cancer Center, Houston
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
招募中1 期
- MD Anderson Cancer Center, Houston
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
招募中1 期
- Baylor St. Luke's Medical Center, Houston
Blue Light Cystoscopy With Cysview® Registry
招募中观察性研究
- Michael E. DeBakey VA Medical Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中观察性研究
- Massive Bio SYNERGY-AI site, Houston
其他城市的 膀胱癌试验
- New York City, NY36 项研究
- Nashville, TN31 项研究
- Dallas, TX27 项研究
- Boston, MA26 项研究
- Washington, DC26 项研究
- Los Angeles, CA25 项研究
- Baltimore, MD24 项研究
- Philadelphia, PA23 项研究
- Edison, NJ23 项研究
- St. Louis, MO22 项研究
- Chicago, IL21 项研究
- Seattle, WA21 项研究
Houston的其他研究
- 非小细胞肺癌143 项研究
- 乳腺癌126 项研究
- 癌症（所有类型）124 项研究
- 结直肠癌101 项研究
- 转移性癌症100 项研究
- 卵巢癌90 项研究
- 急性髓系白血病88 项研究
- 肺癌78 项研究
- 前列腺癌73 项研究
- 子宫内膜癌69 项研究
- 黑色素瘤61 项研究
- 胰腺癌59 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年11月15日。每项研究自行设定入选标准，由研究团队决定谁能参与。